The Economic Burden of Otitis Media in Korea, 2012:A Nationally Representative Cross-Sectional Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Young-Eun | - |
dc.contributor.author | Lee, Ye-Rin | - |
dc.contributor.author | Park, So-Youn | - |
dc.contributor.author | Lee, Kyung Suk | - |
dc.contributor.author | Oh, In-Hwan | - |
dc.date.accessioned | 2022-07-15T07:09:18Z | - |
dc.date.available | 2022-07-15T07:09:18Z | - |
dc.date.created | 2021-05-14 | - |
dc.date.issued | 2016-09 | - |
dc.identifier.issn | 2314-6133 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/153943 | - |
dc.description.abstract | Background. Otitis media (OM) is a common communicable disease that is associated with a substantial economic burden. However, no Korean studies have evaluated OM-related trends after the introduction of the pneumococcal conjugate vaccines. Purpose. This study aimed to estimate the prevalence and economic burden of OM in Korea using nationally representative data. Methods. The burden of OM was estimated nationally representative data such as national health insurance claims data from 2012, based on the prevalence approach and the societal perspective. Results. In 2012, 1,788,303 patients visited medical institutions for treatment of OM, and the prevalence and burden of OM were 3.5% and 497.35 million US dollars, respectively. Patients who were 0-9 years old accounted for 59.7% of the cases and 55.2% of the total cost. Among adults, the total and perpatient costs were highest among 50-59-year-old adults. Direct medical costs and outpatient costs accounted for large proportions of the total cost (86.3% and 88.3%, resp.). Conclusion. The economic burden of OM decreased after the introduction of the pneumococcal conjugate vaccines. However, OM is still associated with a relatively large burden, especially among adults, and interventions are needed to reduce the burden of OM in this population. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | HINDAWI PUBLISHING CORP | - |
dc.title | The Economic Burden of Otitis Media in Korea, 2012:A Nationally Representative Cross-Sectional Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Kyung Suk | - |
dc.identifier.doi | 10.1155/2016/3596261 | - |
dc.identifier.scopusid | 2-s2.0-84989963090 | - |
dc.identifier.wosid | 000384127900001 | - |
dc.identifier.bibliographicCitation | BIOMED RESEARCH INTERNATIONAL, v.2016, pp.1 - 10 | - |
dc.relation.isPartOf | BIOMED RESEARCH INTERNATIONAL | - |
dc.citation.title | BIOMED RESEARCH INTERNATIONAL | - |
dc.citation.volume | 2016 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 10 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | LIFE YEARS DALYS | - |
dc.subject.keywordPlus | ANTIBIOTIC-RESISTANCE | - |
dc.subject.keywordPlus | DISEASES | - |
dc.subject.keywordPlus | PATHOGENS | - |
dc.subject.keywordPlus | INSURANCE | - |
dc.subject.keywordPlus | INJURIES | - |
dc.subject.keywordPlus | CHILDREN | - |
dc.subject.keywordPlus | HISTORY | - |
dc.subject.keywordPlus | CANCER | - |
dc.identifier.url | https://www.hindawi.com/journals/bmri/2016/3596261/ | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.